Legal
Two years after entering into a licensing relationship Canada-based Zymeworks Inc. and Japanese pharma giant Daiichi Sankyo have entered into a second licensing agreement to expand immuno-oncology research with bispecific antibodies.
For the second time in less than one year, Akari Therapeutics is without a chief executive officer. David Horn Solomon abruptly resigned after being caught using the company credit card for personal purposes.
Jazz Pharmaceuticals set aside $57 million in the first quarter of 2018 to settle an investigation by the U.S. Attorney’s Office for the District of Massachusetts regarding its support of 501(c)(3) organizations that provide financial assistance to Medicare patients.
You know when an analyst starts an article with, “Gilead’s Q1 financial results were a disaster,” that it requires a closer look.
Gilead Sciences is facing another round of lawsuits regarding its HIV treatments. This morning the AIDS Healthcare Foundation announced two sets of California-based patients filed a personal injury lawsuit against the Bay Area company regarding safety concerns surrounding its TDF treatment.
Valeant Pharmaceuticals will change its name to Bausch Health Companies Inc. in July of this year. The company will rebrand itself with the highly recognizable name of its subsidiary eye-care company Bausch + Lomb.
Scandals are nothing new in any industry. The pharmaceutical and biotech industry are certainly no strangers to scandals – just ask convicted scandal-magnet Martin Shkreli.
Sam Isaly has finally stepped down from his position as a managing member OrbiMed more than four months after he was accused of sexual harassment. Sexual harassment allegations have been in the forefront of the news cycles for months as the #MeToo movement gained traction.
Patent fights are nothing new in the pharmaceutical industry but a new report shows that during 2017 the number of legal battles of pharmaceutical patents increased by 30 percent.
All that is lacking from the likely drama surrounding patent battles over CRISPR technology in the U.S. Court of Appeals today is Michael Buffer’s cry of “Let’s get ready to rumble.”
PRESS RELEASES